X hits on this document

550 views

0 shares

0 downloads

0 comments

9 / 170

TABLE OF CONTENTS April 1, 2009

Cardiovascular Safety Pharmacovigilance Plan Benefit-Risk Robert Wolf, M.D., F.A.C.C. Vice President Bristol-Myers Squibb

Assessment of Saxagliptin Post-approval Brian Daniels, M.D. Senior Vice President Global Development & Medical Affairs Bristol-Myers Squibb

Clarifying Questions from the Committee to Sponsor

FDA Presentations Naomi Lowy, M.D. Clinical Reviewer CDER, DMEP

Joy Mele, M.S. Statistical Reviewer CDER, Office of Biostatistics

Clarifying Questions from the Committee to FDA

Open Public Hearing Session

Questions from Committee to Sponsor and FDA

Discussion and Questions to the Committee

Voting Questions

###

Scribes, LLC Toll Free 1-800-675-8846 www.scribesllc.com

Page

47

57

59

71

79

86

110

117

121

159

8

Document info
Document views550
Page views550
Page last viewedSun Dec 11 02:29:21 UTC 2016
Pages170
Paragraphs7975
Words54271

Comments